#1Alcon Q3 2023 Earnings Presentation November 15, 2023 Foooooo#2Safe harbor Forward-looking statements This document contains, and our officers and representatives may from time to time make, certain "forward-looking statements" within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "commitment," "look forward," "maintain,” “plan," "goal," "seek," "target," "assume," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our liquidity, revenue, gross margin, operating margin, effective tax rate, foreign currency exchange movements, earnings per share, our plans and decisions relating to various capital expenditures, capital allocation priorities and other discretionary items such as our transformation program, market growth assumptions, our social impact and sustainability plans, targets, goals and expectations, and generally, our expectations concerning our future performance. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict such as: cybersecurity breaches or other disruptions of our information technology systems; compliance with data privacy, identity protection and information security laws; our ability to comply with the US Foreign Corrupt Practices Act of 1977 and other applicable anti-corruption laws, particularly given that we have entered into a three-year Deferred Prosecution Agreement with the US Department of Justice; the impact of a disruption in our global supply chain or important facilities, including our reliance on single source suppliers; supply constraints and increases in the cost of energy; our ability to forecast sales demand and manage our inventory levels and the changing buying patterns of our customers; our ability to manage environmental, social and governance matters to the satisfaction of our many stakeholders, some of which may have competing interests; our success in completing and integrating strategic acquisitions; the success of our research and development efforts, including our ability to innovate to compete effectively; global and regional economic, financial, legal, tax, political and social change; our ability to comply with all laws to which we may be subject; pricing pressure from changes in third party payor coverage and reimbursement methodologies; our ability to properly educate and train healthcare providers on our products; our reliance on outsourcing key business functions; our ability to attract and retain qualified personnel; the impact of unauthorized importation of our products from countries with lower prices to countries with higher prices; the ability to obtain regulatory clearance and approval of our products as well as compliance with any post-approval obligations, including quality control of our manufacturing; our ability to protect our intellectual property; our ability to service our debt obligations; the need for additional financing through the issuance of debt or equity; the effects of litigation, including product liability lawsuits and governmental investigations; effect of product recalls or voluntary market withdrawals; the accuracy of our accounting estimates and assumptions, including pension and other post-employment benefit plan obligations and the carrying value of intangible assets; legislative, tax and regulatory reform; the impact of being listed on two stock exchanges; the ability to declare and pay dividends; the different rights afforded to our shareholders as a Swiss corporation compared to a US corporation; and the effect of maintaining or losing our foreign private issuer status under U.S. securities laws. Additional factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this document speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise. Intellectual property This report may contain references to our proprietary intellectual property. All product names appearing in italics or ALL CAPS are trademarks owned by or licensed to Alcon Inc. Product names identified by a "Ⓡ" or a "TM" are trademarks that are not owned by or licensed to Alcon or its subsidiaries and are the property of their respective owners. Non-IFRS measures Alcon uses certain non-IFRS metrics when measuring performance, including when measuring current period results against prior periods, including core results, percentage changes measured in constant currencies and free cash flow. Because of their non-standardized definitions, the non-IFRS measures (unlike IFRS measures) may not be comparable to the calculation of similar measures of other companies. These non-IFRS measures are presented solely to permit investors to more fully understand how Alcon management assesses underlying performance. These non-IFRS measures are not, and should not be viewed as, a substitute for IFRS measures. Alcon 2#3Agenda 01 Key topics 02 03 05 Sales 04 Core results Alcon IFRS results Outlook ● ●#4Agenda 01 Key topics 02 03 Sales IFRS results 04 Core results Alcon 05 Outlook ● ●#5Q3 2023 Highlights 3Q23 sales of $2.3B, up 8%, or 9% cc¹ 3Q23 operating margin of 12.7%; core operating margin of 19.5% ● ● 3Q23 diluted EPS of $0.41, up 78%, or up 97% cc 3Q23 core diluted EPS¹ of $0.66, up 32%, or up 41% cc¹ Generated $937 million of cash from operating activities and $592 million of free cash flow' in the 9M23 Alcon 1. Constant currency, core operating margin and core diluted EPS and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found in the Appendix. 5#6Q3 2023 Select financial highlights 3rd party sales 3Q23 3Q22 Core diluted EPS¹ 3Q23 3Q22 Alcon $0.50 $2.3B $2.1B $0.66 Core operating margin¹ 3Q23 3Q22 Free cash flow¹ 9M23 9M22 19.5% 17.2% $592M $475M 3Q23 Sales of $2.3B, up 8%, or 9% cc¹ 3Q23 Operating margin of 12.7%, up 300 basis points (bps) y/y; up 420 bps cc 3Q23 Core operating margin of 19.5%, up 230 bps, or up 350 bps cc 1 3Q23 Diluted EPS of $0.41, up 78%, or 97% CC¹ 3Q23 Core diluted EPS of $0.66, up 32%, or up 41% cc¹ 1 9M23 Cash from operating activities of $937M, up from $872M in 9M22 9M23 Free cash flow of $592M, up from $475M in 9M22 1. Constant currency, core operating margin, core diluted EPS and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found in the Appendix. 6#7Agenda 01 Key topics 02 03 05 Sales 04 Core results Alcon IFRS results Outlook ● ●#89M 2023 Product mix¹ Alcon $7.0 billion Alcon 9M23 sales Vision Care $3.1B (44%) Ocular health (41%) Dry eye products Allergy eye drops Steroid eye drops Glaucoma eye drops Contact lens care Contact lenses (59%) Daily lenses Reusable lenses Cosmetic lenses 1. Numbers may be rounded for presentation purposes. Totals may not sum due to rounding. Surgical $4.0B (56%) Implantables (32%) Monofocal IOLS Advanced technology IOLS Glaucoma implants Consumables (51%) Dedicated consumables Custom surgical packs Procedural products Equipment/other (17%) Cataract equipment Retinal equipment Refractive equipment Diagnotics & visualization Equipment service Procedural eye drops 8#9Q3 2023 Surgical Surgical growth in line with market + + Alcon Implantables growth led by demand for advanced technology intraocular lenses in international markets • Continued ATIOL global and US market leadership ● ● ● Consumables growth reflects demand for cataract and vitreoretinal consumables, particularly in international markets, and price increases Equipment growth compared to strong 2022 base; growth primarily driven by demand in international markets -100 bps of negative impact from FX on Surgical growth 1. Constant currency growth is a non-IFRS measure. An explanation of non-IFRS measures can be found in the Appendix. Net Sales (USD $M) $1,216 $392 $618 $206 3Q22 $1,276 $401 $661 $214 3Q23 Implantables Consumables Equipment/other (USD) (CC)¹ 5% 2% 4% 6% 7% 7% 9 5% 5%#10Q3 2023 Vision Care Double-digit Vision Care growth reflects strength in contact lenses and eye drops, including acquired products, and pricing + + Alcon ● ● ● ● Product innovation, including toric modalities of Precision 1, Total30 and Dailies Total1 Price increases across contact lens portfolio Strong demand for portfolio of eye drops, including Rocklatan and Rhopressa; 11 percentage points of growth contribution to Ocular Health from products acquired in 2022 Price increases across ocular health portfolio Declines in legacy lenses 1. Constant currency growth is a non-IFRS measure. An explanation of non-IFRS measures can be found in the Appendix. $908 $558 Net Sales (USD $M) $350 3Q22 $1,027 $612 $415 3Q23 Contact lenses Ocular health (USD) (CC)¹ 13% 13% 10% 9% 19% 20% 10#11Agenda 01 Key topics 02 03 05 Sales 04 Core results Alcon IFRS Results Outlook ●●● 11#12Q3 2023 IFRS results Worldwide net sales $2.3B Alcon $2.1B 3Q22 Y/Y change (USD): 3Q23 +8% Operating margin 9.7% 3Q22 12.7% 3Q23 +300 bps Diluted EPS $0.23 3Q22 $0.41 3Q23 +78% 12#139M 2023 IFRS results Worldwide net sales Alcon $6.5B 9M22 Y/Y change (USD): $7.0B 9M23 +8% Operating margin 11.8% 10.0% 9M22 9M23 +180 bps Diluted EPS $0.87 9M22 $1.10 9M23 +26% 13#14Q3 2023 IFRS operating margin bridge 3Q23 vs. 3Q22, % of net sales Alcon 9.7 3Q22 1.5 Gross Margin 1.9 SG&A (1.2) R&D 2.0 Other income/ expense 13.9 (1.2) Foreign Exchange 12.7 3Q23 14#159M 2023 IFRS operating margin bridge 9M23 vs. 9M22, % of net sales Alcon 10.0 9M22 1.9 Gross Margin 1.6 SG&A (0.8) R&D 0.4 Other income/ expense 13.1 (1.3) Foreign Exchange 11.8 9M23 15